Together, these findings suggest that TVB-3664 as a monotherapy has anti-tumor activity in CRC; however, studies with a larger number of cases are required to establish reliable biomarkers to identify a population of patients that is sensitive to FASN-targeted therapy. The gene discussed is FASN; the disease is neoplasm.